Remove .Net Remove 2017 Remove Competition Remove Report
article thumbnail

10 Negatives That Still Make Going Public A High Risk

Startup Professionals Musings

According to a recent Ernst & Young global report , the first half of 2017 was the most active first half by global number of IPOs since 2007. Public companies of any size must comply immediately with the full reporting requirements of the SEC. With thousands of shareholders, dealing with critics is an onerous challenge.

Startup 87
article thumbnail

Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More

Xconomy

Critics say Mylan has been emboldened by the recall of EpiPen’s only competition last fall. A Phase 2 trial of the drug, AMX0035, should start in late 2016 or early 2017. Frank Vinluan has more on Novan, which relied on a variety of high net worth individuals, rather than venture firms, to get to this point.

Pricing 40